Effect of orlistat on weight and body composition in obese adolescents: A randomized controlled trial

JAMA

Volumn 293, Issue 23, 2005, Pages 2873-2883

  Chanoine, Jean Pierre ^a   Hampl, Sarah ^b   Jensen, Craig ^c   Boldrin, Mark ^d   Hauptman, Jonathan ^d  

^a BC CHILDREN S HOSPITAL   (Canada)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIPID; PLACEBO; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; ENZYME INHIBITOR; LACTONE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ADENOID; ADOLESCENT; ANALYTICAL PARAMETERS; APPENDICITIS; ARTHROPATHY; ARTICLE; ASEPTIC MENINGITIS; ASTHMA; BACKACHE; BEHAVIOR THERAPY; BODY FAT; BODY MASS; BODY WEIGHT; CANADA; CHOLECYSTECTOMY; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DEMOGRAPHY; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FATTY LIVER; FECES; FECES INCONTINENCE; FEMALE; FLATULENCE; GALLBLADDER DISEASE; GALLSTONE; GASTROENTERITIS; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HAY FEVER; HEADACHE; HEPATOMEGALY; HIP; HUMAN; HYPERTROPHY; INSULIN BLOOD LEVEL; LIMB INJURY; LIPID ANALYSIS; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; NOSE SEPTUM; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PILONIDAL SINUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SEIZURE; SINUSITIS; SORE THROAT; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VITAMIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD PRESSURE; BODY COMPOSITION; DRUG ANTAGONISM; DRUG EFFECT; LIPID METABOLISM; METABOLISM; MULTIMODALITY CANCER THERAPY;

ADOLESCENT; ANTI-OBESITY AGENTS; BEHAVIOR THERAPY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIET, REDUCING; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EXERCISE; FEMALE; HUMANS; INSULIN; LACTONES; LIPASE; LIPID METABOLISM; MALE; OBESITY; WEIGHT LOSS;

EID: 20444446770     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.23.2873     Document Type: Article

References (41)

1. Rosner B, Prineas R, Loggie J, Daniels SR. Percentile for body mass index in US children 5 to 17 years of age. J Pediatr. 1998;132:211-222.
2. Barlow SE, Dietz WH; Maternal and Child Health Resources and Services Administration and Department of Health and Human Services. Obesity evaluation and treatment: expert committee recommendations. Pediatrics. 1998;102:E29.
3. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288: 1728-1732.
4. Lobstein T, Baur L, Uauy R; IASO International Obesity TaskForce. Obesity in children and young people: a crisis in public health. Obes Rev. 2004;5(suppl 1): 4-85.
5. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab. 2003;88:1417-1427.
6. Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA. 2003;289:1813-1819.
7. Williams J, Wake M, Hesketh K, Maher E, Waters E. Health-related quality of life of overweight and obese children. JAMA. 2005;293:70-76.
8. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med. 1992;327:1350-1355.
9. Must A. Morbidity and mortality associated with elevated body weight in children and adolescents. Am J Clin Nutr. 1996;63(suppl 3):S445-S447.
10. Thomas-Doberson DA, Butler-Simon N, Fleshner M. Evaluation of a weight management intervention program in adolescents with insulin-dependent diabetes mellitus. J Am Diet Assoc. 1993; 93:535-540.
11. Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA. 1990;264:2519-2523.
12. Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year outcomes of behavioral family-based treatment for childhood obesity. Health Psychol. 1994;13:373-383.
13. Sumerbell CD, Ashton V, Campbell KJ, Edmunds L, Kelly S, Waters E. Interventions for treating obesity in children. Cochrane Database Syst Rev. 2003:CD001872.
14. Epstein LH, Roemmich JN, Raynor HA. Behavioral therapy in the treatment of pediatric obesity. Pediatr Clin North Am. 2001;48:981-993.
15. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805-1812.
16. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: a systematic review of the evidence. JAMA. 1997;278:666-672.
17. Sjöström L, Rissanen A, Andersen T, et al; European Multicenter Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese subjects. Lancet. 1998;352:167-172.
18. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-242.
19. Torgerson J, Hauptman J, Boldrin MN, Sjöström L. Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
20. World Health Organization. Energy and protein requirements. In: Report of a Joint FAO/WHO/UNU Expert Consultation. Geneva, Switzerland: World Health Organization; 1985.
21. Wadden TA, Berkowitz RI. Weight reduction and pride program: special medication issue July 2000. University of Pennsylvania: Philadelphia; 2000.
22. Growth charts. Centers for Disease Control. Available at: http://www.cdc.gov/growthcharts. Accessed February 10, 2005.
23. Goodman E, Daniels SR, Morrison JA, Huang B, Dolan L. Contrasting prevalence of demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. J Pediatr. 2004;145:445-451.
24. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol. 1999;39:41-46.
25. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord. 2003; 27:591-597.
26. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med. 1997; 337:869-873.
27. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
28. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs. 2004;64:2845-2864.
29. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10:642-650.
30. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese subjects with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care. 1998;21:1288-1294.
31. Muls E, Kolanowski J, Scheen A, Van Gaal L. Obel-Hyx Study Group. The effects of orlistat on weight and on serum lipids in obese subjects with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicenter study. Int J Obes Relat Metab Disord. 2001;25:1713-1721.
32. Broom I, Wilding J, Stott P, Myers N; UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract. 2002;56:494-499.
33. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(suppl 3):S12-S23.
34. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995;35:1103-1108.
35. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol. 2004;99:1807-1814.
36. Wabitsch M, Hauner H, Heinze E, et al. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab. 1995;80: 3469-3475.
37. Waldhausen JHT, Benjamin DR. Cholecystectomy is becoming an increasingly common operation in children. Am J Surg. 1999;177:364-367.
38. Wesdorp I, Bosman D, de Graaff A, Aronson D, van der Blij F, Taminiau J. Clinical presentations and predisposing factors of cholelithiasis and sludge in children. J Pediatr Gastroenterol Nutr. 2000;31:411-417.
39. Jeffrey RW, McGuire MT, Brelje KL, et al. Recruitment to mail and telephone interventions for obesity in a managed care environment: the Weight-To-Be Project. Am J Manag Care. 2004;10:378-382.
40. Porter JA, Raebel MA, Conner DA, et al. The Longterm Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care. 2004;10:369-376.
41. Wirth A. Reduction of body weight and comorbidities by orlistat: the XXL Primary Health Care Trial. Diabetes Obes Metab. 2005;7:21-27.